As the environment for quick-service restaurant operators slowly rebounds, Dunkin' Brands, which includes Dunkin' Donuts and Baskin-Robbins, is brewing an appropriately priced IPO.
Veterinary segments may contain hidden value for both Patterson and Schein.
We are very positive on the prospects for the company, but even good companies should be bought for less than they are worth.
Our first take on the social networking giant's IPO.
Despite LPL's secular growth opportunities, we're skeptical of the asset-management services firm's profitability.
The dialysis industry is in a state of flux, but business models remain intact.
With significantly improved results in North America and a strong financial position, GM is likely ready to test the IPO waters.
We like the stable cash-flow profile at Chesapeake Midstream Partners, whose IPO is scheduled for later this week.
We worry about lingering product delays, new order potential, and whether the company can truly become profitable.
CBOE should generate strong long-term returns, but the IPO doesn't look cheap.
We think the time is right to bring this high-quality IPO to market.
Primerica's marketing structure is not our only concern.
This Brazilian toll road operator holds an attractive investment profile buttressed by a narrow moat.
The IPO of financial services software firm SS&C is compelling for several reasons.
AOL is not without its issues, but the shares look cheap.
We see little room for optimism for this hotel IPO.
What sets some mortgage REIT IPOs apart from the others.
Despite its strong investment track record, Artio's shareholder structure leaves much to be desired.
The absence of a public plan within the bill has health-care companies breathing a sigh of relief.
The Brazilian banking oligopoly gives IPO Santander Brasil impressive pricing power, but risks of government intervention remain.
Santander Brasil is primed to benefit from opportunities in Brazil's lucrative banking market.
This for-profit education IPO operates in a very strong industry and has plenty of upside potential, but it faces more risks than many of its rivals.
Ancestry.com has built a respectable, niche business, but we are skeptical about the sustainability of revenue growth.
This upcoming IPO has room to grow in Brazil's lucrative banking market.
While currently a leader in the lucrative and fast-growing online gaming market, several factors make us wary of this IPO's longer-term prospects.
Though we like the asset management business in general, Artio has a much higher risk profile than many of its peers.
Hybrid car battery developer A123 is in line to go public Thursday, but we're not charged up on the company.
Long-run trends appear to be clearly in this IPO's favor.
Hyatt is looking to raise $1 billion. But for what?
Cumberland Pharmaceutical is already profitable, but is it worth the offer price?
Health-care analyst Brian Laegeler likes the fact that specialty pharma IPO Cumberland is already profitable, but a weak pipeline and a pricey offer price are concerns.
Talecris Biotherapeutics could be one of the largest IPOs of the year.
The largest IPO north of the border in two years was rolled out under a veil of secrecy, but could it power up investors' portfolios?
Cardinal Health's CareFusion spin-off is worthy of investors' attention.
As the LogMeIn IPO logs big first-day gains, analyst Rafael Garcia offers his take on the software-solutions provider and the current stock price.
We like the firm's products, but we're a little sour on the economics of the business
The dental industry has attractive long-term characteristics.
The IPO of Visanet, the Brazilian affiliate of credit card processor Visa, could raise close to $5 billion. Get our take on the firm's prospects.
Firms are getting creative in the midst of suddenly dormant public markets.